Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Draadje OT, bijzaken & geleuter in de marge!

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Draadje OT, bijzaken & geleuter in de marge!

1.189 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 60 »» | Laatste | Omlaag ↓
  1. [verwijderd] 4 april 2006 16:12
    quote:

    zeker schreef:

    Nu Crucell kopen of vasthouden wat je al hebt.
    Zodra de stijging inzet, je aandelen verkopen en omzetten in call opties (call opies kopen)!

    Deze call opties weer verkopen zodra de boel stabiliseert (op de dag van het PB) en je aandelen Crucell dezelfde of de volgende dag weer terugkopen (long positie aandelen weer op hold).

    Snap ie? ;-))

    Grtz,
    ZEKER
    Zeker.

    :-))

    Is dit ook voorkennis; flinke daling met behoorlijke omzet?

    Dirk.
  5. [verwijderd] 4 april 2006 20:25
    Custom-made bladders produced from patients' own cells
    Medical Research News
    Published: Tuesday, 4-Apr-2006

    Scientists in the U.S. have produced custom-made bladders grown from patients' own cells which have been have been successfully transplanted and function well.
    The team from the Institute of Regenerative Medicine at Wake Forest University in North Carolina say they have shown that regenerative medicine techniques can be used to generate functional bladders that are durable.

    The bladders showed improved function over time with some patients being followed for more than seven years.
    Lead researcher Dr. Anthony Atala, director of the Institute, says it suggests that regenerative medicine may one day be a solution to the shortage of donor organs for those needing transplants.
    Seven patients were given new bladders engineered from a plug of tissue grown from their own, dysfunctional bladders and this meant they did not need to take drugs to prevent organ rejection, as do patients given transplants from either living or dead donors.
    Atala's team has been working for 16 years to find ways to first identify and separate immature cells known as progenitor cells from the patients' bladders.
    They then coaxed the cells to grow on a scaffold into the two main cell types found in bladders.
    The patients, children and teens aged 4 to 19, had poor bladder function because of a congenital birth defect that causes incomplete closure of the spine.
    Their bladders were not pliable and the high pressures could be transmitted to their kidneys, possibly leading to kidney damage.
    www.news-medical.net/?id=17114
    **************
    4 April 2006
    Bladder tissue-engineering: a new practical solution?
    Destination Journal: The Lancet

    Research in cell-based bladder tissue-engineering began about two decades ago. In today's Lancet, Anthony Atala and colleagues report the first human clinical trial with engineered bladders. Seven patients with myelomeningocele and resultant dysfunctional bladders underwent bladder augmentations with autologous, smooth muscle, and urothelial cell-seeded scaffolds. The engineered tissue improved overall bladder function in all patients, with mean follow-up of almost 4 years. .....

  6. forum rang 10 voda 4 april 2006 23:35
    Grappig!
    (uit de koffiekamer)


    lexpen - 4 apr 06, 15:32 | Reageer | Quote | Zoek | Aanbevolen: 0

    Jean, dat ben ik met je eens.
    Maar neem nou die belegger die in februari hoopvol stukken Crucell voor 21 euro kocht.
    Omdat hij het continue koersdrukken helemaal zat was, leverde hij medio maart zijn stukken maar weer in voor 19,90 (heel waarschijnlijk aan de manipulerende partij).
    Heel jammer want net voordat er een 20% rally naar 24 euro plaatsvond.
    Koersdrukken is bedoeld om vooral beleggers met een kortere horizon onzeker en moedeloos te maken, om ze afscheid te laten nemen van hun positie.
  7. [verwijderd] 5 april 2006 07:44
    CRUCELL (CRXL:AMS) Midkap Euronext Amsterdam(AMX) 22,35 (0,00%)

    actuele gegevens van CRUCELL
    beurs Midkap slotkoers 22,35 EUR 04-04
    actuele koers 22,35 EUR 05-04 07:26 openingskoers -- EUR --
    hoogste -- EUR --
    laagste -- EUR --
    volume --
    Orderboek Bieden Laten
    Tijd Aantal Koers Koers Aantal Tijd
    05-04 07:24 1.500 AT BEST 23,09 1.900 05-04 07:24
    05-04 07:24 45 23,09 23,10 35 05-04 07:24
    05-04 07:24 447 22,40 23,15 529 05-04 07:24
    05-04 07:24 25 22,37 23,18 1.350 05-04 07:24
    05-04 07:24 100 22,35 23,20 2.400 05-04 07:24

    Duid dit op eeen hogere opening?

  8. [verwijderd] 5 april 2006 07:59
    Beursverslagen: Oooh-cé
    Europese beurzen sloten de handelsdag gisteren met verlies af. Amsterdam noteerde 0,7% lager. De dalende dollar beïnvloedde bedrijven zoals Philips die veel omzetten in de VS. Grootste stijger was TomTom met 4,6%, gevolgd door Rodamco Europe en Buhrmann. Onderaan de lijst stonden Getronics (-2,9%), Hagemeyer en ASML. UBS verhoogde het koersdoel van TNT. Morgan Stanley heeft achttien miljoen aandelen Ahold verkocht, het fonds sloot 0,6% lager. Arcelor is een tegenoffensief tegen Mittal begonnen, Mittal won 3,6%. De Midkap is 0,8% lager de dag uitgegaan, vooral Océ moest het ontgelden met een dagverlies van 8,2%. Vopak pakte de dagwinst met 1,1%. Isotis won 1,6%, het heeft toestemming voor het gebruik van twee botvervangers. Crucell en Pharming moesten beiden inleveren.

  9. [verwijderd] 5 april 2006 09:23
    ImCLone prevails in dispute with Germany's Merck Tue Apr 4, 7:38 AM ET

    NEW YORK (Reuters) - ImClone Systems Inc. (Nasdaq:IMCL - news) said on Tuesday that an arbitrator has decided in its favor in a dispute with German drugs and chemicals maker Merck KGaA (MRCG.DE) over rights to develop and commercialize an antibody used in cancer treatment.

    ImClone said in a statement that the decision, which is binding and cannot be appealed, gives it exclusive rights to develop and commercialize the monoclonal antibody IMC-11F8 outside the United States and Canada.

    Commercial rights to this antibody in the United States, Canada and Japan fall within the scope of ImClone's commercial agreement with Bristol-Myers Squibb (NYSE:BMY - news) regarding cancer drug Erbitux.
    news.yahoo.com/s/nm/20060404/bs_nm/im...
    ********
    Merck sees higher-than-expected Q1 results Tue Apr 4, 9:13 AM ET

    CHICAGO (Reuters) - Merck & Co. Inc. (NYSE:MRK - news) on Tuesday said it expects its first-quarter results to top its prior view, boosted by strong sales of its Zocor cholesterol drug.

    The Whitehouse Station, New Jersey-based drugmaker said it sees first-quarter earnings per share in the range of 71 cents to 75 cents, excluding restructuring charges. It sees net first-quarter earnings in the range of 61 cents per share to 67 cents per share.

    Analysts on average have expected earnings per share of 64 cents in the first quarter, according to Reuters Estimates.

    Merck backed its full-year 2006 earnings outlook of $2.28 per share to $2.36 per share, excluding items.
    news.yahoo.com/s/nm/20060404/bs_nm/me...
  10. [verwijderd] 5 april 2006 14:43
    RTRS-Nederland loopt achter in biotechnologie
    AMSTERDAM (ANP) - Nederland loopt achter op het gebied van
    biotechnologie in vergelijking met andere Europese landen. Dat
    blijkt uit een woensdag gepubliceerd onderzoek van
    adviesorganisatie Ernst & Young over de wereldwijde
    ontwikkelingen in deze jonge sector.

    Met de zes medicijnen in de pijplijn in 2005, waarvan maar
    één in de laatste ontwikkelingsfase, staat Nederland op een
    lijst van vijftien landen op de elfde plek. Nederland moet onder
    meer België en Oostenrijk boven zich dulden. Engeland en
    Zwitserland, van oudsher sterke farmalanden, waren goed voor
    ruim 60 procent van de 523 potentiële geneesmiddelen.

    Ook gemeten naar de uitgaven aan onderzoek en ontwikkeling
    als percentage van het bruto binnenlands product speelt
    Nederland de tweede viool. De biotechsector was vorig jaar goed
    voor 1,6 procent van de totale omvang van de geproduceerde
    goederen en diensten in Nederland. Daarmee geeft Nederland
    relatief nauwelijks meer geld uit aan biotechnologisch onderzoek
    dan Slovenië.

    Volgens de onderzoekers van Ernst & Young is Nederland laat
    ingestapt. Ook ontbreekt het Nederland aan grote farmabedrijven
    en durfkapitalisten die grote sommen geld in de biotechsector
    steken. De ontwikkeling van een medicijn vergt een lange adem.
    Volgens onderzoeker Pieter Lucas van Ernst & Young duurt het
    gemiddeld zeven jaar voordat een medicijn wat oplevert.
    Bovendien is er een groot risico dat het geneesmiddel de
    eindstreep helemaal niet haalt.

    De Nederlandse biotechsector doet het wel goed op de beurs.
    Van de vier Nederlandse beursgenoteerde biotechbedrijven zijn
    Crucell en Pharming, beide uit Leiden, inmiddels doorgestoten
    tot de index van middelgrote fondsen (MidKap-index) op de
    Amsterdamse beurs. De beurswaarde van de twee fondsen
    verdubbelde het afgelopen jaar bijna.

    Uit het onderzoek van Ernst & Young blijkt verder dat de
    Europese biotechsector na een aantal jaren van
    herstructureringen de weg naar boven heeft hervonden. Zo lag het
    aantal beursintroducties in Europa (23) vorig jaar hoger dan in
    de Verenigde Staten (13). Voor het eerst haalde Europa meer
    kapitaal (3,2 miljard euro) op dan de VS. Volgens Lucas heeft
    dit vooral te maken met ,,de prop van 2004''. Daarmee bedoelde
    hij het verbeterde beursklimaat in Europa na het magere
    beursjaar 2004.

    Overigens loopt Europa op biotech nog mijlenver achter op de
    VS. Gemeten naar omzet is Europa goed voor 15 procent van de
    wereldwijde biotechomzet tegen driekwart voor de VS.

    Wereldwijd beleefde de biotechsector in 2005 volgens Ernst &
    Young een topjaar. De nog jonge sector, dertig jaar geleden
    ontstaan, bereikte vorig jaar een recordomzet van ruim 63
    miljard dollar. De verliezen, in de woorden van Lucas
    ,,investeringen in onderzoek en ontwikkeling'', werden
    gehalveerd tot 4,4 miljard dollar. Het advieskantoor verwacht
    dat door het afgelopen succesvolle jaar de sector als geheel wel
    eens voor 2008 zwarte cijfers kan laten zien.

    ((Maarten Dijksma, email economie(at)anp.nl, +31 20 504
    5999))
  11. [verwijderd] 5 april 2006 20:04
    En dan dit:

    Ebola virus best way to kill billions and save world: ecologist

    Last Updated Tue, 04 Apr 2006 18:13:08 EDT
    CBC News
    A respected Texas scientist says the best way to kill 90 per cent of the people on the planet and save the world is the Ebola virus.

    "HIV is too slow," Eric Pianka said. "It's no good."


    Biology professor Eric Pianka is known as the 'doomsday ecologist' for his controversial views on population growth. (Courtesy Eric Pianka)
    Pianka, a 67-year-old biology professor at the University of Texas in Austin, can't understand why people object to his views.

    "I don't bear any ill will towards anybody," Pianka said as he discussed the death threats, the jeering and the protests since his views became public last week. "I've got two granddaughters, man. I'm putting money in a college fund for my granddaughters. I'm worried about them."

    He doesn't want to harm anybody, said Pianka, who has since backed off somewhat from his original comments. He just believes that the world has far too many people. The population of the world is estimated at six billion.
    "What we really need to do is start thinking about controlling our population before it's too late," he told the Associated Press. "It's already too late, but we're not even thinking about it. We're just mindlessly rushing ahead breeding our brains out."

    Labelled the "doomsday ecologist," Pianka is a latter-day Thomas Malthus, the 19th-century British economist who said there were too many people in the world. Malthus wanted to control human breeding to prevent overpopulation and starvation, ideas that were picked up 200 years later by the Chinese government.

    Pianka approves of Chinese theories on birth control. But he goes one step further and advocates the use of the Ebola virus to kill off the world's surplus people.
    "If we don't control our population, microbes will," he said. "Why do we have these lethal microbes that kill us in the first place? The answer is, there's too many of us."

    Starvation and war will inevitably decimate the world's population, he says. But diseases, such as the Ebola virus, offers the most efficient and fastest way to "kill the billions that must soon die if the population crisis is to be solved."
    Pianka's unique view of the world extends to his own personality. His website shows an elderly man standing in the scrub of central Texas with a tangled grey beard, ragged clothing and a four-foot long monitor lizard.

    He has even pre-written his obituary, presumably in case he's first in line for the Ebola virus.

    The website shows a man who has unique views on the world, but is also a highly-respected scientist.
    He describes himself as "The Lizard Man." He says he became a cripple at the age of 13 when he set off a bazooka shell that he picked up on an army base and developed gangrene in his leg. He also spent 10 years as a hermit in the desert and he lives with a herd of bison.
    But he went on to become an eminent, award-winning scientist with 20 books and hundreds of scientific papers under his belt, studies at Ivy League Princeton University and positions on a host of scientific boards.

    He has been a Guggenheim Fellow and a Fulbright Senior Research Fellow. He was even made a Distinguished Texas Scientist by the eminent Texas Academy after giving a speech earlier this year on his population ideas.
    Pianka's views have caused a stir in Austin, where he studies lizards at the local university.
    "We have a lot of different points of view on the University of Texas at Austin campus. And we certainly support our faculty in saying what they think," said Don Hale, spokesman for the University of Texas.
    "They have the right to express their point of view," he said. "But they're expressing their personal point of view."
    www.cbc.ca/story/science/national/200...

  12. gogogoo 5 april 2006 22:22
    Meet Kuno
    by: trudythemonkey (18/F/The jungle)
    Long-Term Sentiment: Strong Buy 04/04/06 05:23 am
    Msg: 25202 of 25242

    Introducing Kuno Sommer

    Kuno Sommer, formerly the CEO of Berna Biotech, has now been appointed as Crucell’s Chief Business Officer:

    “The fact that we have now managed to complete and close the deal on the merger of Berna Biotech with Crucell is a great achievement and very good news from my perspective. This event, which is significant in our long history and tradition of success, will put us in pole position for the future development of our operations.

    “Berna Biotech, with its great know-how about developing, producing, marketing and selling vaccines in many countries around the world, fits extremely well with Crucell’s knowledge and experience of developing new technologies.

    “The aim is now for us all to concentrate on establishing a new organization that takes the very best of both companies and creates an even stronger enterprise. If we get it right and succeed in fitting Berna Biotech and Crucell together, which I am sure we can do, we will have a very powerful combination with a high potential for growth and the confidence to compete successfully on the world market in the future.”
  14. [verwijderd] 5 april 2006 23:14
    Via Yahoo( by: beleggerjan )

    Confessions of a Paid Stock Basher

    Following was posted on the PTII board, I thought I'll let u know that, make up your mind:
    Begin:
    Today I want to come clean about something I feel very badly about. I cannot undo some of the things I have done, but hopefully this message will prevent other such occurrences in the future.

    I am a paid basher.
    Yes, it is true. Today is my last day at this company; I'm moving on to a new job. I've realized that there are more dignifying jobs out there that can pay me equally as well. But before I go, I want to explain a few things because this just isn't right and I won't feel good about myself until I expose this sham. It's hurt too many people and I don't want it on my conscience anymore. I can no longer live with a lie.

    I work for a company called Global Calumny Funds in Stamford, CT. Basically, it's a Boiler Room much like the one in the movie of the same name. The idea behind my group is to bash the price of a company's stock down low enough to where the group of investors who retained our company's services can buy the stock really cheap and perhaps even take it over all together.
    There are approximately 70 people at the company divided into several groups. My group, consisting of 5 people, is responsible for IDWD. While I probably shouldn't give any names of anyone working here now, what the heck, I'm leaving here, so what can they do? sue me? Ha! I can tell you that laptoptrader and janice shell were part of my group until he left last week, as was ninaturtle. Others who have been part of this include early bashers like hard data and Investorman. You may be interested to know that some hypsters, such as MONEYMADE and even Datatech!!, have also been part of the scam (more on that later).
    There are several companies engaged in the bashing business, ours is not the only one. However, I can tell you that not every basher in here is a paid basher. Having done this for a year, I can usually tell who is a paid basher and who is merely someone
    having a little fun. While unpaid bashers have a different motive than someone like me, they can be unwilling accomplices to helping me achieve my ultimate goal and they also spread rumor and confusion throughout a room, which also helps me.

    What is that goal? Well, I am merely a cog in a much larger machine, so my bosses never really explained the big picture to me, but I'd say essentially, Shaddowwatch2oo3 was right. There are several companies who are quite familiar with Jim Bishop and Janice Shell and who are deathly afraid of them.
    There are three types of bashers here at Global Calumny Funds: Advanced, Intermediate and Beginner. An Advanced-level basher (also known as a Silver Tongued Devil) would spread false or misleading information about the company.
    They would deal in facts, countering every longs post with articles, news reports and opinion surveys that gave a negative impression about the company.
    An Intermediate-level basher (also known as a Serpent) would try to weasel their way into the confidence of longs and create doubt using rumor or innuendo.

    Finally, a Beginner-level basher (also known as a Pitchfork) would attempt to create confusion in the room by distracting other posters with satire, name calling and pointless arguments. The idea was to make sure no serious discussion of the stock
    could take place. A Pitchfork was usually a basher, but not always. Sometimes, we would throw in a hypster Pitchfork such as MONEYMADE and laptop and a pumper like Datatech to create the illusion of an argument going on. What was really funny (in a perverse way, I guess) was that Datatech and I sat next to each other, laughing the whole time.

    I was a Serpent basher, because I am known for effective bashing based on solid facts and truth. I was paid a base wage of $18 an hour for my services. I was given a $1.25 bonus for every decent quality post over 100 per day as well as a monthly bonus of $100 for every penny the stock had dropped from the previous month. I was also paid a bonus for bashing on weekends. While this may not sound like much, I made a decent, though dishonorable, paycheck plus a nice Laptop with free wireless internet connection.

    Each of us sat in a small half-cubicle in a cluster with our teammates. Each group (usually five people) was made of three beginners (two who would bash and one who would hype), one intermediate and one advanced level basher. Occasionally for some
    of the hotter stocks, one of the beginners would be replaced by an intermediate depending on how much the stock was rising. IDWD was a low-level stock, meaning it got the 3-1-1 configuration.

    Honestly though, somehow, I get the feeling that WV Hillbilly may have worked for a basher company or knows someone who does because the fund websites he occasionally posts is eerily similar to our employer's websites. While not exact, I'd say it is about 90 percent the same. We do have certain rules that we follow.

    First, we have to develop a character and stay within that character in order to build a "following." My character, "FogOfWar," was a humorous, sarcastic, obnoxious supporter of free speech and loved to portray himself as a truth-telling superhero, but only when it came to bashers.

    Next, we had to follow certain guidelines on what we could say. We were urged to have an "answer" to every long's question, but we were to frame that answer in a way that ridiculed the questioner for asking such a question. However, we were never to use profanity or vulgarity because that would cause people to ignore us. We were to make fun of people, but in a civil way. The idea was to get "play," i.e. reaction from other posters. The more play we got, the more the room would be disrupted. Ignored posters get no play. One exception would be the hypsters since they were "defending" the stock against our onslaught, they got a little more leeway. People would side with the hypster because they thought he was real since he appeared to be on their side, but was really on ours, setting us up to disrupt the room. MoneyMade was quite good at this and gets paid very well.

    I've worked on IDWD, VLO, AGII, QBID, BKMP for a few months now. In addition to the FogOfWar alias, I've used a few others on several other boards as well. I've used so many aliases that I can not remember the monikers or the passwords. I honestly lost track of everything. I stuck with FogOfWar because it was the one that got the most play from other posters.

    In closing, I feel absolutely terrible about this. It's just awful how I've been part of a scam designed to cheat honest, hard-working people out of their investments all for the
    benefit of a few wealthy people who already have enough money to last a lifetime.
    These greedy people MUST be stopped. That's why I'm posting this before I leave. I want to make up for some of the damage I've done. I can't live with this lie anymore. You can't imagine how hard it is to look at myself in the mirror each morning knowing my job is to cheat and lie.
    I have to go now, I'm too broken up to continue. I hope this confession can make up for my sordid deeds; I would urge everyone who reads this to inform as many people as you can. Only by shining the light of truth can we drive these rats back into the darkness from whence they came. Believe me, they don't want publicity.
  16. [verwijderd] 6 april 2006 08:02
    RTRS-Klant wil beloning van zijn verzekeringsadviseur kennen
    DEN HAAG (ANP) - De discussie over de provisies die
    adviseurs in de verzekeringswereld ontvangen, heeft ook de
    belangstelling van klanten gewekt. Tweederde van de consumenten
    heeft interesse in de beloning die een tussenpersoon krijgt voor
    het sluiten van een verzekering. Twee jaar geleden toonde minder
    dan de helft belangstelling voor de provisies.

    Dat blijkt uit de jaarlijkse Consumentenmonitor die het
    Verbond van Verzekeraars donderdag heeft gepubliceerd. Bijna de
    helft van alle consumenten schakelt een tussenpersoon in om een
    verzekering af te sluiten. Vooral mensen met een lagere of
    gemiddelde opleiding geven de voorkeur aan een adviseur. Hoger
    opgeleiden sluiten hun verzekering liever direct af bij de
    verzekeraar.

    De beloning die assurantietussenpersonen ontvangen van
    verzekeraars heeft de afgelopen jaren voor een flinke discussie
    gezorgd. De hamvraag was of tussenpersonen wel onafhankelijk
    advies geven aan hun klanten als zij bij de verkoop van het ene
    verzekeringsproduct een hogere vergoeding ontvangen dan bij de
    verkoop van een soortgelijk product van een andere verzekeraar.
    Minister Zalm van Financiën heeft afgelopen jaar een akkoord
    gesloten met de financiële sector, waardoor adviseurs inzicht
    moeten gaan geven in de opbouw van hun beloning.

    Het onderzoek van de verzekeringskoepel leert ook dat het
    gros van de consumenten nog altijd ,,financieel analfabeet'' is
    en weinig trek heeft om daar iets aan te veranderen. De klant
    wil volgens de onderzoekers maar één ding: ,,Als er financiële
    problemen zijn, moet de verzekeraar deze wegnemen.'' Een groep
    hoog opgeleiden met een hoog inkomen vormt een uitzondering op
    de gedesinteresseerde klant. In deze groep valt 35 procent van
    de Nederlanders.

    Als klanten onverwachts met verzekeringsrisico's worden
    geconfronteerd, vinden ze dat een ,,onprettige verrassing'',
    aldus de onderzoekers. Het imago van verzekeraars is daarvan
    volgens hen de dupe. Dat imago staat behoorlijk onder druk.
    Vorig jaar stond nog 63 procent van de consumenten positief
    tegenover verzekeraars, afgezet tegen 80 procent in 2003. De
    verzekeraars noemen de onzekerheid rond het nieuwe
    ziektekostenstelsel en verzekeringen voor arbeidsongeschiktheid
    als mogelijke oorzaak van de daling.

    ((Paul van der Zanden, email economie(at)anp.nl, +31 20 504
    5999))
  17. [verwijderd] 6 april 2006 08:03
    RTRS-Heineken komt met meer bieren voor Beertender
    AMSTERDAM (ANP) - Heineken gaat het assortiment voor zijn thuistap
    Beertender uitbreiden. Vanaf april kunnen liefhebbers van Murphy's Irish Red,
    Affligem Blond en Wieckse Witte ook thuistappen. In het najaar zijn Amstel Bock,
    Amstel 1870 en Brand Urtyp beschikbaar.

    Alle merken komen uit de stal van Heineken. De bierbrouwer sluit niet uit
    dat op termijn bieren van andere producenten beschikbaar komen. Wieckse Witte en
    Amstel Bock zaten overigens vorig jaar al tijdelijk in het assortiment. De
    bierbrouwer verkoopt het hele jaar door vaatjes van Heineken, Amstel en Brand.

    Heineken maakte woensdag bekend dat 180.000 tapsystemen zijn verkocht sinds
    de introductie twee jaar geleden. Meer dan vier miljoen vaatjes gingen over de
    toonbank. De Beertender is nu te koop in Nederland, Oostenrijk en Zwitserland.
    Heineken wil dit jaar nog drie markten op, maar welke zijn nog geheim.

    De bierbrouwer wil zich niet in de kaart laten kijken door zijn
    belangrijkste concurrent Inbev. De Belgische brouwer ging eind 2004 met Philips
    de boer op met PerfectDraft. Dit systeem, waarover Heineken met Philips in de
    clinch ligt over vermeende patentinbreuk, is verkrijgbaar in Nederland, België
    en Duitsland. Eind vorig jaar hadden 30.000 consumenten een PerfectDraft in
    huis. Op dit systeem zijn niet alleen Inbevs eigen merken (onder meer Dommelsch
    en Hertog Jan) verkrijgbaar. Grolsch en Bavaria leveren ook bier.

    ((Rianne Groot, email economie(at)anp.nl, +31 20 504 5999))

    Jammie! Lekker, lekker.
  18. [verwijderd] 6 april 2006 08:40
    RTRS-Merck veroordeeld in Vioxx-zaak
    WASHINGTON (ANP) - Het Amerikaanse farmacieconcern Merck
    moet 4,5 miljoen dollar betalen aan een man die langdurig de
    pijnstiller Vioxx heeft geslikt. Het middel heeft eraan
    bijgedragen dat de man een hartaanval heeft gekregen, zo
    oordeelde woensdag een juryrechtbank.

    De rechtszaak kreeg extra aandacht omdat die de eerste was
    die ging over de gevolgen van het langdurig gebruik van de
    pijnstiller. Bij eerdere zaken, waarin Merck werd vrijgesproken,
    kon worden aangetoond dat een kort gebruik van Vioxx niet
    schadelijk is.

    Merck haalde in september 2004 de pijnstiller van de markt na
    publicaties over schadelijke bijwerkingen ervan. Bij gebruik
    gedurende minstens achttien maanden bleek de kans op een
    hartaanval te verdubbelen. Sinds die tijd zijn er duizenden
    rechtszaken tegen het farmacieconcern aangespannen.

    ((ANP Redactie Economie, email economie(at)anp.nl, +31 20
    504 5999))
  19. [verwijderd] 6 april 2006 10:24
    Genentech gives $2.5M to Cold Spring Harbor lab
    Wednesday April 5, 1:37 pm ET

    Genentech Inc. said Wednesday it gave $2.5 million to the Cold Spring Harbor Laboratory to create a biotechnology history center.
    biz.yahoo.com/bizj/060405/1268894.htm...
    *******************

    ....strakjes kijken naar de geschiedenis van STAR...het begin van een nieuw tijdperk!
    gr.
  20. [verwijderd] 6 april 2006 10:27
    Vaccine hailed as 80% guard against cervical cancer

    Polly Curtis, health correspondent
    Thursday April 6, 2006
    The Guardian

    The cervical cancer vaccine could be even more effective than previously thought, giving protection against the sexually transmitted infections that cause 80% of all cervical cancers, scientists say today.
    The vaccine had been proved to offer protection against two forms of the human papilloma virus (HPV), known as HPV-16 and HPV-18, which are linked to 70% of cervical cancers. But research from the US published today in the Lancet online suggests the vaccine could also guard against HPV-31 and HPV-45.

    It raises the question of whether the vaccine will replace the national screening programme, which picks up 80% of cancers, though experts warned that take-up of the vaccine would have to be 100% for it to be as effective as the programme. Cervical cancer kills more than 1,000 women a year in the UK.

    Separate research suggests that a widespread vaccination programme against the disease could be undermined by parents' distrust of vaccines: 20% of parents refuse to let their children be vaccinated.

    Two firms are racing to get a licence for the HPV vaccine. Today's update on trials of the Cervarix vaccine, developed by GlaxoSmithKline, suggests women are protected against the virus, and stay free of side effects, for four and a half years after being vaccinated.

    Diane Harper, of Dartmouth Medical School, New Hampshire, said: "These findings set the stage for the widescale adoption of HPV vaccination for prevention of cervical cancer."

    The trial results add to evidence that the cervical cancer vaccine may not require regular booster jabs.

    The firm Sanofi Pasteur MSD is also developing a vaccine, called Gardasil, and has applied for a European licence.

    Anne Szarewski, head of Cancer Research UK's vaccination programme, said: "For the vaccine to give 80% protection, you'd have to ensure 100% of girls have it, and the chances are, that won't happen."

    The University of Manchester research on parental attitudes, led by Loretta Brabin, suggests 20% of girls would miss out on the vaccination because of parental mistrust following the row over links between the MMR jab and autism.

    The cervical cancer jab would have to be given to girls before the onset of puberty, between the age of 10 and 12, to maximise its effectiveness. One in five parents asked about their attitudes would be put off going ahead either because of their opposition to childhood vaccination, or because of worries that a jab viewed as being against a sexually transmitted disease might encourage sexual activity. Only 38% of parents asked said they definitely approved of the vaccine.

    "Linking cervical cancer to a potentially stigmatising [sexually transmitted infection] risks a negative impact on vaccine uptake," suggests the paper, published in the journal Vaccine.
    society.guardian.co.uk/health/story/0,,1747867,00.html?gusrc=rss
1.189 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 60 »» | Laatste |Omhoog ↑

Direct naar Forum

Indices

AEX 882,27 -0,04%
EUR/USD 1,0722 +0,25%
FTSE 100 8.147,03 +0,09%
Germany40^ 18.126,20 -0,19%
Gold spot 2.334,57 -0,14%
NY-Nasdaq Composite 15.927,90 +2,03%

Stijgers

Philip...
+29,35%
Alfen ...
+14,76%
EBUSCO...
+6,88%
FASTNED
+4,79%
EXOR NV
+3,96%

Dalers

Vastned
-6,87%
VIVORY...
-5,88%
ASMI
-4,39%
ADYEN NV
-2,42%
BESI
-2,42%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!